Tuberculosis remains one of the most consequential infectious disease challenges of our era, and a sweeping new analysis now offers the most granular accounting yet of who is dying, where, and why — arriving precisely as global health funding cuts threaten to unravel decades of hard-won progress. For anyone tracking longevity and disease burden at a population level, this dataset reframes both the scale of the problem and the fragility of recent gains.
Drawing on the Global Burden of Disease Study 2023 framework, researchers modeled TB incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 through 2023, stratifying all estimates by HIV co-infection status and drug-resistance profile — including multidrug-resistant TB (MDR-TB). The analytical architecture integrated global vital registration records, surveillance data, verbal autopsy findings, and minimally invasive tissue sampling to construct cause-of-death estimates via the Cause of Death Ensemble model, while DisMod-MR 2.1 simultaneously reconciled morbidity parameters. A population attributable fraction framework was applied to isolate the independent contributions of alcohol use, smoking, and elevated fasting plasma glucose to the overall TB burden — three modifiable risk factors with direct relevance to lifestyle medicine.
The scope and methodology here elevate this beyond a routine surveillance report. GBD-scale analyses are among the few tools capable of revealing regional divergences that country-level reports obscure — and the explicit layering of HIV status onto MDR-TB estimates is particularly significant, since HIV-positive individuals face disproportionate MDR-TB mortality risk. The WHO End TB Strategy targets a 95% reduction in deaths and 90% drop in incidence by 2035 from 2015 baselines; this analysis provides the most rigorous interim benchmark to assess whether those trajectories are achievable. The inclusion of modifiable metabolic and behavioral risk factors signals an important conceptual shift — framing TB not solely as an infectious disease problem but as one intertwined with chronic disease risk profiles. Key limitations include the inherent uncertainty in verbal autopsy data and the reliance on country-reported surveillance quality, which varies enormously. Nonetheless, for health-conscious adults and policymakers alike, this study anchors the conversation about infectious disease longevity threats to data, not estimates.